Atea Pharmaceuticals, Inc. (AVIR) Income Statement
AVIR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAVIR revenue and net income
AVIR profit margins
AVIR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AVIR quarterly EPS vs estimates
Atea Pharmaceuticals beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.50).
AVIR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $192.2M | $351.4M | $48.6M | $0 | $0 |
| Cost of revenue | $416,000 | $83.4M | $70.1M | $260,000 | $29,000 | $38.0M | $17,000 | $17,000 |
| Gross profit | −$416,000 | −$83.4M | −$70.1M | −$260,000 | $351.4M | $10.6M | −$17,000 | −$17,000 |
| Research & development | $148.0M | $145.4M | $132.8M | $81.9M | $167.2M | $38.0M | $10.2M | $6.7M |
| Sales, general & admin | $32.9M | $48.8M | $49.9M | $48.7M | $45.8M | $21.6M | $4.4M | $2.8M |
| Total operating expenses | $180.9M | $109.6M | $94.1M | $130.7M | $213.0M | $21.6M | $14.6M | $9.5M |
| Operating income | −$180.9M | −$192.9M | −$164.2M | −$130.7M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| Interest income | $16.4M | $25.5M | $29.2M | $11.2M | $213,000 | $83,000 | $574,000 | $413,000 |
| Interest expense | — | — | — | $11.2M | $242,000 | $83,000 | $0 | $0 |
| Income before taxes | −$164.5M | −$167.5M | −$134.9M | −$119.5M | $138.6M | −$10.9M | −$14.0M | −$9.1M |
| Income taxes | −$6.2M | $925,000 | $1.0M | −$3.6M | $17.4M | −$83,000 | −$574,000 | $413,000 |
| Net income | −$158.3M | −$168.4M | −$136.0M | −$115.9M | $121.2M | −$10.9M | −$13.5M | −$9.1M |
| EBITDA | −$164.1M | −$131.8M | −$119.6M | −$130.4M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| EPS (diluted) | −$1.94 | −$2.00 | −$1.64 | −$1.40 | $1.34 | −$0.97 | −$0.28 | −$0.21 |
| Gross margin | — | — | — | −0.1% | 100.0% | 21.8% | — | — |
| Operating margin | — | — | — | −68.0% | 39.4% | −22.7% | — | — |
| Net margin | — | — | — | −60.3% | 34.5% | −22.5% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $416,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $104,000 | $104,000 | $38.2M | $2.4M | $3.4M | $104,000 | $19.9M | $104,000 | $104,000 | $104,000 | $18.1M |
| Gross profit | — | −$104,000 | −$104,000 | −$38.2M | −$2.4M | −$3.4M | −$104,000 | −$19.9M | −$104,000 | −$104,000 | −$104,000 | −$18.1M |
| Research & development | $28.1M | $41.1M | $47.8M | $38.3M | $32.3M | $29.6M | $25.7M | $26.2M | $34.7M | $57.6M | $35.0M | $31.9M |
| Sales, general & admin | $6.9M | $6.9M | $7.1M | $7.2M | $9.1M | $9.5M | $13.4M | $11.0M | $12.3M | $12.3M | $11.6M | $12.6M |
| Total operating expenses | $35.1M | $47.9M | $54.9M | $7.3M | $38.9M | $35.6M | $38.9M | $17.3M | $46.8M | $69.7M | $46.5M | $22.7M |
| Operating income | −$35.1M | −$48.0M | −$54.9M | −$45.6M | −$41.3M | −$39.0M | −$39.0M | −$37.2M | −$46.9M | −$69.8M | −$46.6M | −$40.8M |
| Interest income | $2.2M | $2.6M | $3.3M | $3.7M | $4.4M | $5.0M | $5.7M | $6.3M | $6.6M | $6.9M | $7.8M | $7.9M |
| Income before taxes | −$32.9M | −$45.4M | −$51.6M | −$41.9M | −$37.0M | −$34.1M | −$33.3M | −$30.9M | −$40.3M | −$62.9M | −$38.8M | −$32.9M |
| Income taxes | $24,000 | $50,000 | −$6.8M | $196,000 | $207,000 | $203,000 | $225,000 | $226,000 | $243,000 | $231,000 | $349,000 | $221,000 |
| Net income | −$32.9M | −$45.4M | −$44.9M | −$42.0M | −$37.2M | −$34.3M | −$33.5M | −$31.2M | −$40.5M | −$63.2M | −$39.2M | −$33.1M |
| EBITDA | −$32.8M | −$45.3M | −$51.5M | −$41.7M | −$41.3M | −$34.0M | −$33.2M | −$30.9M | −$40.2M | −$62.8M | −$38.7M | −$30.6M |
| EPS (diluted) | −$0.41 | −$0.57 | −$0.57 | −$0.53 | −$0.44 | −$0.40 | −$0.40 | −$0.37 | −$0.48 | −$0.75 | −$0.47 | −$0.40 |
| Gross margin | — | — | — | — | — | — | −25.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −9,381.2% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −8,063.2% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AVIR's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AVIR financial results
Atea Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $158.3 million. Diluted earnings per share came to −$1.94.
See the AVIR stock overview for the latest quote and news, or the AVIR chart for price history and technical indicators.
AVIR income statement FAQ
Does Atea Pharmaceuticals have revenue?
Atea Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Atea Pharmaceuticals profitable?
No. Atea Pharmaceuticals reported a net loss of $158.3 million in fiscal 2025.
How much does Atea Pharmaceuticals spend on research and development?
Atea Pharmaceuticals spent $148.0 million on research and development in fiscal 2025.
What are Atea Pharmaceuticals's earnings per share?
Atea Pharmaceuticals earned $-1.94 per diluted share in fiscal 2025, compared with $-2.00 a year earlier.
When will Atea Pharmaceuticals report its next earnings?
Atea Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes.
When does Atea Pharmaceuticals's fiscal year end?
Atea Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.